Skip to main content
. 2016 Nov 3;7(47):76374–76389. doi: 10.18632/oncotarget.13062

Figure 4. Differential response of PIK3CA mutated BLCAb001 and BLCAb002 to LY414.

Figure 4

A. PI3KCA mutations in BLCAb001 (E452K) and BLCAb002 (E545K). Color codes- Yellow orange color indicates P13K alpha helical domain. B. Anti-tumor effects of LY414 on PDXs BLCAb001 and BLCAb002 tumors (upper panels), tumor weights at the end of treatment (EOT) (lower panels). C.. Western blot analysis of the effect of LY414 treatment on p-AKT, p-mTOR, and pS6 in BLCAb001 and BLCAb002 PDXs. D. Effect of LY414 on BLCAb001 and BLCAb002 cells isolated from PDX cultured in DMEM. Statistical analysis of ANOVA was performed to determine the significance p≤ 0.001. E. Western blot analysis of the effect of LY414 treatment on p-AKT and p-S6K in BLCAb001 and BLCAb002 derived cells cultured in DMEM.